Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Peri

Showing results (71-80 of 92) with videos related to

Pageof 10
Sort By:
Bioconjugate Chemistry|May 29, 2019
Synthesis of the New Cyanine-Labeled Bacterial Lipooligosaccharides for Intracellular Imaging and in Vitro Microscopy StudiesTung-Cheng Wang, Florent Cochet, Fabio Alessandro Facchini, et al.
Cell Death & Disease|February 17, 2018
Toll-like receptor 4 modulation influences human neural stem cell proliferation and differentiationChiara Grasselli, Daniela Ferrari, Cristina Zalfa, et al.
Innate Immunity|March 4, 2025
Preclinical development of the TLR4 antagonist FP12 as a drug lead targeting the HMGB1/MD-2/TLR4 axis in lethal influenza infectionKari Ann Shirey, Alessio Romerio, Mohammed Monsoor Shaik, et al.
Scientific Reports|January 21, 2017
TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infectionLaure Perrin-Cocon, Anne Aublin-Gex, Stefania E Sestito, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 24, 2022
Istaroxime Metabolite PST3093 Selectively Stimulates SERCA2a and Reverses Disease-Induced Changes in Cardiac FunctionMartina Arici, Mara Ferrandi, Paolo Barassi, et al.
Chembiochem : a European Journal of Chemical Biology|December 17, 2013
Modulation of CD14 and TLR4·MD-2 activities by a synthetic lipid A mimeticRoberto Cighetti, Carlotta Ciaramelli, Stefania Enza Sestito, et al.
Scientific Reports|January 31, 2019
Novel carboxylate-based glycolipids: TLR4 antagonism, MD-2 binding and self-assembly propertiesFlorent Cochet, Fabio A Facchini, Lenny Zaffaroni, et al.
Journal of Medicinal Chemistry|March 21, 2024
Novel TLR4-Activating Vaccine Adjuvant Enhances the Production of <i>Enterococcus faecium</i>-binding AntibodiesAna Rita Franco, Océane Sadones, Alessio Romerio, et al.
Journal of Translational Medicine|January 19, 2024
Selective SERCA2a activator as a candidate for chronic heart failure therapyMartina Arici, Shih-Che Hsu, Mara Ferrandi, et al.
Chemmedchem|February 20, 2009
Design, synthesis, and biological evaluation of levoglucosenone-derived ras activation inhibitorsChristian Müller, Maria Antonia Gomez-Zurita Frau, Dario Ballinari, et al.
Pageof 10

Showing results (71-80 of 92) with videos related to

Sort By:
Pageof 10
Bioconjugate Chemistry|May 29, 2019
Synthesis of the New Cyanine-Labeled Bacterial Lipooligosaccharides for Intracellular Imaging and in Vitro Microscopy StudiesTung-Cheng Wang, Florent Cochet, Fabio Alessandro Facchini, et al.
Cell Death & Disease|February 17, 2018
Toll-like receptor 4 modulation influences human neural stem cell proliferation and differentiationChiara Grasselli, Daniela Ferrari, Cristina Zalfa, et al.
Innate Immunity|March 4, 2025
Preclinical development of the TLR4 antagonist FP12 as a drug lead targeting the HMGB1/MD-2/TLR4 axis in lethal influenza infectionKari Ann Shirey, Alessio Romerio, Mohammed Monsoor Shaik, et al.
Scientific Reports|January 21, 2017
TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infectionLaure Perrin-Cocon, Anne Aublin-Gex, Stefania E Sestito, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 24, 2022
Istaroxime Metabolite PST3093 Selectively Stimulates SERCA2a and Reverses Disease-Induced Changes in Cardiac FunctionMartina Arici, Mara Ferrandi, Paolo Barassi, et al.
Chembiochem : a European Journal of Chemical Biology|December 17, 2013
Modulation of CD14 and TLR4·MD-2 activities by a synthetic lipid A mimeticRoberto Cighetti, Carlotta Ciaramelli, Stefania Enza Sestito, et al.
Scientific Reports|January 31, 2019
Novel carboxylate-based glycolipids: TLR4 antagonism, MD-2 binding and self-assembly propertiesFlorent Cochet, Fabio A Facchini, Lenny Zaffaroni, et al.
Journal of Medicinal Chemistry|March 21, 2024
Novel TLR4-Activating Vaccine Adjuvant Enhances the Production of <i>Enterococcus faecium</i>-binding AntibodiesAna Rita Franco, Océane Sadones, Alessio Romerio, et al.
Journal of Translational Medicine|January 19, 2024
Selective SERCA2a activator as a candidate for chronic heart failure therapyMartina Arici, Shih-Che Hsu, Mara Ferrandi, et al.
Chemmedchem|February 20, 2009
Design, synthesis, and biological evaluation of levoglucosenone-derived ras activation inhibitorsChristian Müller, Maria Antonia Gomez-Zurita Frau, Dario Ballinari, et al.
Pageof 10